150 related articles for article (PubMed ID: 22580984)
21. Silencing of HEPN1 is responsible for the aggressive biological behavior of pituitary somatotroph adenomas.
Peng H; Fan J; Wu J; Lang J; Wang J; Liu H; Zhao S; Liao J
Cell Physiol Biochem; 2013; 31(2-3):379-88. PubMed ID: 23548416
[TBL] [Abstract][Full Text] [Related]
22. Heregulin regulates prolactinoma gene expression.
Vlotides G; Cooper O; Chen YH; Ren SG; Greenman Y; Melmed S
Cancer Res; 2009 May; 69(10):4209-16. PubMed ID: 19401448
[TBL] [Abstract][Full Text] [Related]
23. Role of matrix metalloproteinase 9 in pituitary tumor behavior.
Turner HE; Nagy Z; Esiri MM; Harris AL; Wass JA
J Clin Endocrinol Metab; 2000 Aug; 85(8):2931-5. PubMed ID: 10946906
[TBL] [Abstract][Full Text] [Related]
24. Pituitary specific transcription factor messenger ribonucleic expression in adenomatous and nontumorous human pituitary tissues.
Lloyd RV; Jin L; Chandler WF; Horvath E; Stefaneanu L; Kovacs K
Lab Invest; 1993 Nov; 69(5):570-5. PubMed ID: 8246449
[TBL] [Abstract][Full Text] [Related]
25. Effects of 17 beta-estradiol and medroxyprogesterone acetate upon MtTW15 mammosomatotropic pituitary tumor growth and hormone production in male and female rats.
Winneker RC; Parsons JA
Cancer Res; 1981 May; 41(5):1772-7. PubMed ID: 7214344
[TBL] [Abstract][Full Text] [Related]
26. Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas.
Williams JC; Stone D; Smith-Arica JR; Morris ID; Lowenstein PR; Castro MG
Mol Ther; 2001 Dec; 4(6):593-602. PubMed ID: 11735344
[TBL] [Abstract][Full Text] [Related]
27. Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression.
Kaliberova LN; Kusmartsev SA; Krendelchtchikova V; Stockard CR; Grizzle WE; Buchsbaum DJ; Kaliberov SA
Mol Cancer Ther; 2009 Nov; 8(11):3130-9. PubMed ID: 19887544
[TBL] [Abstract][Full Text] [Related]
28. 15-hydroxyprostaglandin dehydrogenase is downregulated and exhibits tumor suppressor activity in gastric cancer.
Song HJ; Myung SJ; Kim IW; Jeong JY; Park YS; Lee SM; Nam WH; Ryu YM; Fink SP; Yang DH; Jung HY; Kim JH
Cancer Invest; 2011 May; 29(4):257-65. PubMed ID: 21469975
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of survivin splice variants in pituitary tumors.
Waligórska-Stachura J; Andrusiewicz M; Sawicka-Gutaj N; Kubiczak M; Jankowska A; Liebert W; Czarnywojtek A; Waśko R; Blanco-Gangoo AR; Ruchała M
Pituitary; 2015 Jun; 18(3):410-6. PubMed ID: 25107550
[TBL] [Abstract][Full Text] [Related]
30. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
31. Role of KCNAB2 expression in modulating hormone secretion in somatotroph pituitary adenoma.
Ashton C; Rhie SK; Carmichael JD; Zada G
J Neurosurg; 2020 Feb; 134(3):787-793. PubMed ID: 32109873
[TBL] [Abstract][Full Text] [Related]
32. The Effects of Smad3 on Adrenocorticotropic Hormone-Secreting Pituitary Adenoma Development, Cell Proliferation, Apoptosis, and Hormone Secretion.
Zhou YZ; Li CZ; Gao H; Zhang YZ
World Neurosurg; 2018 Jun; 114():e329-e337. PubMed ID: 29524699
[TBL] [Abstract][Full Text] [Related]
33. Expression of Neuropeptide Y and Its Relationship with Molecular and Morphological Changes in Human Pituitary Adenomas.
Jia R; Li M; Chang B; Chen L; Ma J
Cancer Biother Radiopharm; 2015 Dec; 30(10):411-9. PubMed ID: 26683132
[TBL] [Abstract][Full Text] [Related]
34. Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
Tai HH; Chi X; Tong M
Prostaglandins Other Lipid Mediat; 2011 Nov; 96(1-4):37-40. PubMed ID: 21763448
[TBL] [Abstract][Full Text] [Related]
35. GH/PRL-secreting pituitary macroadenoma associated with GNAS p.Gln227Leu mutation: pediatric case report and review.
Watanabe D; Yagasaki H; Kojika S; Ogiwara M; Kinouchi H; Nakane T; Inukai T
Endocr J; 2019 May; 66(5):403-408. PubMed ID: 30814395
[TBL] [Abstract][Full Text] [Related]
36. Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription.
Shimon I; Hüttner A; Said J; Spirina OM; Melmed S
J Clin Invest; 1996 Jan; 97(1):187-95. PubMed ID: 8550832
[TBL] [Abstract][Full Text] [Related]
37. Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression.
Horwitz GA; Miklovsky I; Heaney AP; Ren SG; Melmed S
Mol Endocrinol; 2003 Apr; 17(4):600-9. PubMed ID: 12554778
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-2: Prognostic biological markers in invasive prolactinomas.
Gültekin GD; Çabuk B; Vural Ç; Ceylan S
J Clin Neurosci; 2015 Aug; 22(8):1282-7. PubMed ID: 26071077
[TBL] [Abstract][Full Text] [Related]
39. Combining Cadherin Expression with Molecular Markers Discriminates Invasiveness in Growth Hormone and Prolactin Pituitary Adenomas.
Chauvet N; Romanò N; Meunier AC; Galibert E; Fontanaud P; Mathieu MN; Osterstock G; Osterstock P; Baccino E; Rigau V; Loiseau H; Bouillot-Eimer S; Barlier A; Mollard P; Coutry N
J Neuroendocrinol; 2016 Feb; 28(2):12352. PubMed ID: 26686489
[TBL] [Abstract][Full Text] [Related]
40. β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.
Smartt HJ; Greenhough A; Ordóñez-Morán P; Talero E; Cherry CA; Wallam CA; Parry L; Al Kharusi M; Roberts HR; Mariadason JM; Clarke AR; Huelsken J; Williams AC; Paraskeva C
Gut; 2012 Sep; 61(9):1306-14. PubMed ID: 22082586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
